Square Pharmaceuticals PlcDSEBD: SQURPHARMA

SQURPHARMA: Six-month net profit surged 16% year-over-year on strong revenue and cash flow growth

· Issued by Square Pharmaceuticals Plc

Net revenue for the six months ended 31 December 2025 rose 15% year-over-year to Tk. 43.38 billion, with profit after tax up 16% to Tk. 14.68 billion. EPS and net operating cash flow per share both showed strong growth, reflecting robust business recovery and operational efficiency.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Square Pharmaceuticals

All Square Pharmaceuticals news releases